motavizumab
mAbexperimental
Motavizumab is a humanized monoclonal antibody. It is being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it was undergoing Phase II and III clinical trials. — Wikipedia
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00192465)
Timeline
Indications
Mechanism of action
- Fusion glycoprotein F0INHIBITOR
F inhibitor
Targets a highly conserved epitope in the A antigenic site of the RSV fusion (F) protein, which is important in the invasion of RSV from cell to cell.
- RSV F-proteinImmunity, passive
RSV F-protein immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMotavizumab ↗
- ChEMBLCHEMBL1743042 ↗
Also known as
- medi-524
- medi-524
- medi-524
- medi-524
- motavizumab
- motavizumab
- motavizumab
- motavizumab
- numax
- numax
- numax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00628303 | Phase 3 | Oct 1, 2010 | MedImmune |
| NCT00435227 | Phase 2 | Mar 1, 2007 | MedImmune |
| NCT00421304 | Phase 2 | Jan 1, 2007 | MedImmune |
| NCT00316264 | Phase 2 | Apr 1, 2006 | MedImmune |
| NCT00538785 | Phase 2 | Oct 1, 2005 | MedImmune |
| NCT00113490 | Phase 1/Phase 2 (Phase 2) | May 1, 2005 | MedImmune |
| NCT00129766 | Phase 3 | Nov 1, 2004 | MedImmune |
| NCT00121108 | Phase 3 | Nov 1, 2004 | MedImmune |
| NCT00192504 | Phase 1 | Mar 1, 2004 | MedImmune |
| NCT00192478 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2004 | MedImmune |
| NCT00192465 | Phase 1 | Nov 1, 2003 | MedImmune |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 11 | 11 | 3 | 2003 |
1 organizations
Page 1 / 1